[Alpha-1-antitrypsin deficiency associated with chronic bronchopneumopathy and essential emphysema].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to J Kofman.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
We compared the effects of two alpha-adrenoceptor antagonists, nicergoline and phentolamine, on myocardial oxygen consumption (MVO2) in open-chest dogs. Intravenous nicergoline, 2 micrograms/kg/min for 30 min, reduced blood pressure from 130 +/- 6 to 100 +/- 2 mm Hg, did not change heart rate, and reduced MVO2/beat from 63.1 +/- 6.6 to 43.6 +/- 4.0 microliters (p less than 0.05, compared with control saline-infused and phentolamine-treated dogs). Intravenous phentolamine, 8 micrograms/kg/min, reduced blood pressure from 123 +/- 6 to 95 +/- 8 mm Hg and increased heart rate from 199 +/- 4 to 235 +/- 9 beats/min ( p less than 0.05, compared with control and nicergoline-treated dogs). MVO2/beat did not change, but MVO2 increased from 11.1 +/- 1.5 to 13.1 +/- 2.0 ml/min (p less than 0.05, compared with nicergoline-treated dogs). These results suggest that nicergoline may be preferable to phentolamine in patients in whom it is important to avoid any increase in MVO2.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.